The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort
Little is known about the value of adding concurrent chemotherapy (CC) to radiotherapy for stage II nasopharyngeal carcinoma (NPC) with undetectable (0 copies/mL) pretreatment Epstein-Barr Virus (EBV) DNA in the intensity-modulated radiotherapy (IMRT) era. To address this question, the present study...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-02-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320304824 |
| _version_ | 1818383478280945664 |
|---|---|
| author | Ya-Nan Jin Qing-Nan Tang Ji-Jin Yao Xi-Wei Xu Wen-Zhuo He Lei Wang Ya-Fei You Kun-Wei Peng Chang Jiang Liang-Ping Xia |
| author_facet | Ya-Nan Jin Qing-Nan Tang Ji-Jin Yao Xi-Wei Xu Wen-Zhuo He Lei Wang Ya-Fei You Kun-Wei Peng Chang Jiang Liang-Ping Xia |
| author_sort | Ya-Nan Jin |
| collection | DOAJ |
| description | Little is known about the value of adding concurrent chemotherapy (CC) to radiotherapy for stage II nasopharyngeal carcinoma (NPC) with undetectable (0 copies/mL) pretreatment Epstein-Barr Virus (EBV) DNA in the intensity-modulated radiotherapy (IMRT) era. To address this question, the present study retrospectively reviewed 514 patients with newly diagnosed stage II NPC and undetectable pretreatment EBV DNA from Sun Yat-sen University Cancer Center between March 2008 and October 2016. Clinical characteristics and survival outcomes between concurrent chemoradiotherapy (CCRT) and IMRT alone groups were compared. Propensity score matching analysis was conducted to control for confounding factors. Although CCRT group had significantly higher proportions of stage N1 disease than IMRT alone group before matching (85% vs. 61%, p < 0.001), no statistically significant differences were noted for OS (97.8% vs. 98.1%, p = 0.700), DFS (93.4% vs. 94.5%, p = 0.846), DMFS (96.0% vs. 96.9%, p = 0.762), and LRFS (97.3% vs. 98.1%, p = 0.701). After 1:1 propensity-score matching, 177 pairs were identified. Patients in each group were found to be well balanced in baseline characteristics and risk factors (all P > 0.05). The five-year OS (96.9% vs. 98.2%, p = 0.302), DFS (92.0% vs. 95.2%, p = 0.777), DMFS (95.2% vs. 97.6%, p = 0.896), and LRFS (97.3% vs. 97.6%, p = 0.328) rates remain comparable for both CCRT and RT alone groups. Additionally, subgroup analysis still failed to observe any significant survival benefit for the addition of CC to IMRT for N1 disease (P>0.05 for all). Our results indicated that IMRT alone appeared to achieve comparable survival to CCRT for stage II NPC with undetectable pretreatment EBV DNA. |
| first_indexed | 2024-12-14T03:07:00Z |
| format | Article |
| id | doaj.art-b5e12b5f74fe4ebb828e39867f9ccc98 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-14T03:07:00Z |
| publishDate | 2021-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-b5e12b5f74fe4ebb828e39867f9ccc982022-12-21T23:19:22ZengElsevierTranslational Oncology1936-52332021-02-01142100990The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohortYa-Nan Jin0Qing-Nan Tang1Ji-Jin Yao2Xi-Wei Xu3Wen-Zhuo He4Lei Wang5Ya-Fei You6Kun-Wei Peng7Chang Jiang8Liang-Ping Xia9VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, ChinaDepartment of Head and Neck Oncology, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Biomedical Imaging, Zhuhai 519001, Guangdong, ChinaDepartment of Head and Neck Oncology, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Biomedical Imaging, Zhuhai 519001, Guangdong, ChinaVIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, ChinaVIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, ChinaVIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, ChinaVIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, ChinaVIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China; Corresponding authors.VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China; Corresponding authors.Little is known about the value of adding concurrent chemotherapy (CC) to radiotherapy for stage II nasopharyngeal carcinoma (NPC) with undetectable (0 copies/mL) pretreatment Epstein-Barr Virus (EBV) DNA in the intensity-modulated radiotherapy (IMRT) era. To address this question, the present study retrospectively reviewed 514 patients with newly diagnosed stage II NPC and undetectable pretreatment EBV DNA from Sun Yat-sen University Cancer Center between March 2008 and October 2016. Clinical characteristics and survival outcomes between concurrent chemoradiotherapy (CCRT) and IMRT alone groups were compared. Propensity score matching analysis was conducted to control for confounding factors. Although CCRT group had significantly higher proportions of stage N1 disease than IMRT alone group before matching (85% vs. 61%, p < 0.001), no statistically significant differences were noted for OS (97.8% vs. 98.1%, p = 0.700), DFS (93.4% vs. 94.5%, p = 0.846), DMFS (96.0% vs. 96.9%, p = 0.762), and LRFS (97.3% vs. 98.1%, p = 0.701). After 1:1 propensity-score matching, 177 pairs were identified. Patients in each group were found to be well balanced in baseline characteristics and risk factors (all P > 0.05). The five-year OS (96.9% vs. 98.2%, p = 0.302), DFS (92.0% vs. 95.2%, p = 0.777), DMFS (95.2% vs. 97.6%, p = 0.896), and LRFS (97.3% vs. 97.6%, p = 0.328) rates remain comparable for both CCRT and RT alone groups. Additionally, subgroup analysis still failed to observe any significant survival benefit for the addition of CC to IMRT for N1 disease (P>0.05 for all). Our results indicated that IMRT alone appeared to achieve comparable survival to CCRT for stage II NPC with undetectable pretreatment EBV DNA.http://www.sciencedirect.com/science/article/pii/S1936523320304824Nasopharyngeal carcinomaEpstein–Barr virus DNASurvivalIntensity-modulated radiotherapyConcurrent chemotherapyEffect |
| spellingShingle | Ya-Nan Jin Qing-Nan Tang Ji-Jin Yao Xi-Wei Xu Wen-Zhuo He Lei Wang Ya-Fei You Kun-Wei Peng Chang Jiang Liang-Ping Xia The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort Translational Oncology Nasopharyngeal carcinoma Epstein–Barr virus DNA Survival Intensity-modulated radiotherapy Concurrent chemotherapy Effect |
| title | The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort |
| title_full | The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort |
| title_fullStr | The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort |
| title_full_unstemmed | The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort |
| title_short | The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort |
| title_sort | effect of adding concurrent chemotherapy to radiotherapy for stage ii nasopharyngeal carcinoma with undetectable pretreatment epstein barr virus dna retrospective analysis with a large institutional based cohort |
| topic | Nasopharyngeal carcinoma Epstein–Barr virus DNA Survival Intensity-modulated radiotherapy Concurrent chemotherapy Effect |
| url | http://www.sciencedirect.com/science/article/pii/S1936523320304824 |
| work_keys_str_mv | AT yananjin theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT qingnantang theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT jijinyao theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT xiweixu theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT wenzhuohe theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT leiwang theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT yafeiyou theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT kunweipeng theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT changjiang theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT liangpingxia theeffectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT yananjin effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT qingnantang effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT jijinyao effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT xiweixu effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT wenzhuohe effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT leiwang effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT yafeiyou effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT kunweipeng effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT changjiang effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort AT liangpingxia effectofaddingconcurrentchemotherapytoradiotherapyforstageiinasopharyngealcarcinomawithundetectablepretreatmentepsteinbarrvirusdnaretrospectiveanalysiswithalargeinstitutionalbasedcohort |